Home » Newsletters » BioWorld Science

BioWorld Science

June 15, 2015

View Archived Issues

Isis Pharmaceuticals updates on phase II trial of ISIS-SMNRx in infants with type I SMA

Tioga Pharmaceuticals begins phase II study of asimadoline in patients with pruritus

NCCN receives funding from Boehringer Ingelheim to study afatinib combinations in NSCLC

Merrimack expands MM-398 imaging study to patients with metastatic breast cancer

Adamas starts phase II trial of amantadine ER in patients with MS and walking impairment

Immune Pharmaceuticals licenses topical ciclosporin formulation from Yissum

Johnson & Johnson announces multiple collaborations

First preclinical data presented on ORM-23048 for neuropathic pain

Bristol-Myers Squibb patents EZH2 inhibitors

Canadian scientists describe withanolide analogues

Pharmakea discloses autotaxin inhibitors

Tolerability and activity assessed with ASP-2215 in patients with acute myeloid leukemia

PTC Therapeutics develops BMI-1 inhibitors

Daiichi Sankyo divulges LCAT activators

Novel DNA vaccine shows promising preclinical efficacy

New antibody for IBD tested at Sumitomo Dainippon Pharma

FDA awards breakthrough therapy designation to SER-109

Novel Nanofitin targeting TNF-alpha for IBD

Cancer vaccine developer Targovax merges with oncolytic virus firm Oncos

First phase I/II data for Delta-Fly Pharma's DFP-10917 in acute myeloid leukemia

KemPharm reports data from abuse liability trial of KP-201/acetaminophen

Servier licenses European rights to Taiho's TAS-102

BioAtla receives equity investment from Chinese investor group

Roswell Park Cancer Institute spins out OmniSeq

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...